Injecting acidic nanoparticles into mice in a model of Parkinson’s disease protected against nerve cell loss and restored the ability of lysosomes, cell compartments responsible for breaking down excess or damaged proteins, to work as they should, a research team reported. “Our results support lysosomal re-acidification as a disease-modifying strategy for…
Combining a 12-week program of virtual reality (VR) training and motor imagery exercises with standard physical therapy (PT) significantly lessened motor symptoms — including tremors, slow movements (bradykinesia), and postural instability — among people with Parkinson’s disease, according to a recent study. “To the best of our knowledge, this…
Early results from the Phase 2 clinical trial of oral SAGE-718 showed the investigative therapy’s use was associated with cognitive gains in people with mild impairment due to Parkinson’s disease. These findings were presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimer’s and Parkinson’s…
OccamzRazor has received $6.1 million in investments to support its artificial intelligence (AI)- based platform aimed at accelerating the identification of new therapeutic targets for Parkinson’s disease. With the technology, which uses AI to analyze data from many published sources, novel treatment targets can be identified and…
Data from a new U.K. study with the most diverse group of patients ever reported show that Parkinson’s disease symptoms — including tremors, cognitive difficulties, epilepsy, and hearing loss — can emerge up to 10 years before a diagnosis. Moreover, ethnicity or socioeconomic status were not found to be associated with…
Parkinson’s disease patients don’t appear to be at an increased risk for side effects after getting the COVID-19 vaccination compared with the general population, and reported having fewer reactions to it than healthy participants in a small study. “Our data showed few [adverse events] reported after…
A first patient with Parkinson’s disease has been dosed with UB-312, Vaxxinity’s experimental vaccine therapy targeting alpha-synuclein, after treatment safety and tolerability was seen in healthy volunteers in a clinical trial. This marks the beginning of Part B in the Phase 1 trial (NCT04075318), which is enrolling up…
Get regular updates to your inbox.